<DOC>
	<DOCNO>NCT00798304</DOCNO>
	<brief_summary>The primary purpose study evaluate safety immunogenicity investigational meningococcal B vaccine healthy infant .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Immunogenicity Meningococcal B Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Investigators always use good clinical judgment consider subject 's overall fitness trial participation . In addition , condition opinion investigator may interfere evaluation study objective carefully consider prior enrol subject . Male female subject age 2 month ( 42 98 day age ) time enrollment . Available entire consented period whose parent/legal guardian reach telephone . Healthy infant determine medical history , physical examination , judgment investigator . Parent/legal guardian must able complete relevant study procedure study participation . Previous vaccination license investigational vaccine : meningococcal B , meningococcal C , pneumococcal , Hib , diphtheria , tetanus , acellular pertussis , poliovirus , rotavirus , varicella , measles , mumps , rubella . Any following illnesses/conditions , investigator 's judgment , substantially increase risk associate subject 's participation completion study : A previous anaphylactic reaction vaccine vaccinerelated component . Contraindication vaccination meningococcal B , meningococcal C , pneumococcal , Hib , diphtheria , tetanus , acellular pertussis , Hepatitis B ( HBV ) , poliovirus , rotavirus , varicella , measles , mumps , rubella . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . Known suspected immune deficiency suppression . History cultureproven invasive disease cause N meningitidis Neisseria gonorrhoea . Major know congenital malformation serious chronic disorder . Significant neurological disorder history seizure include febrile seizure , significant stable evolve disorder cerebral palsy , encephalopathy , hydrocephalus , significant disorder . Does include resolve syndrome due birth trauma Erb palsy . Receipt blood product gammaglobulin ( include hepatitis B immunoglobulin monoclonal antibody ) . Received investigational drug , vaccine device ( aside specify protocol ) within 4 week administration first dose test article time throughout study . Participation purely observational study acceptable . Infant direct descendant ( child , grandchild ) study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Meningococcal B vaccine</keyword>
	<keyword>infant</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>